Race, rituximab, and relapse in TTP

for the United States Thrombotic Microangiopathies Consortium, Elizabeth Davis

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black patients are overrepresented in iTTP cohorts in the United States, but racial disparities in iTTP outcome and response to therapy have not been studied. Using the United States Thrombotic Microangiopathies Consortium iTTP Registry, we evaluated the impact of race on mortality and relapse-free survival (RFS) in confirmed iTTP in the United States from 1995 to 2020. We separately examined the impact of rituximab therapy and presentation with newly diagnosed (de novo) or relapsed iTTP on RFS by race. A total of 645 participants with 1308 iTTP episodes were available for analysis. Acute iTTP mortality did not differ by race. When all episodes of iTTP were included, Black race was associated with shorter RFS (hazard ratio [HR], 1.60; 95% CI, 1.16-2.21); the addition of rituximab to corticosteroids improved RFS in White (HR, 0.37; 95% CI, 0.18-0.73) but not Black patients (HR, 0.96; 95% CI, 0.71-1.31). In de novo iTTP, rituximab delayed relapse, but Black patients had shorter RFS than White patients, regardless of treatment. In relapsed iTTP, rituximab significantly improved RFS in White but not Black patients. Race affects overall relapse risk and response to rituximab in iTTP. Black patients may require closer monitoring, earlier retreatment, and alternative immunosuppression after rituximab treatment. How race, racism, and social determinants of health contribute to the disparity in relapse risk in iTTP deserves further study.

Original languageEnglish (US)
Pages (from-to)1335-1344
Number of pages10
Issue number12
StatePublished - Sep 22 2022

Bibliographical note

Funding Information:
This study was supported by grants K99HL150594 (S.C.) and UL1TR001111 and UL1TR002494, the National Institutes of Health Clinical and Translational Science Awards to the University of North Carolina at Chapel Hill and the University of Minnesota, for data maintenance and security of the REDCap databases used to house the data for this study. No industry support was provided. The visual abstract was created with Biorender.com.

Publisher Copyright:
© 2022 American Society of Hematology


Dive into the research topics of 'Race, rituximab, and relapse in TTP'. Together they form a unique fingerprint.

Cite this